Loading clinical trials...

Determining the Feasibility of Outpatient Parenteral Antibiotic Therapy for Persons Who Inject Opioids | Clinical Trials | Clareo Health

COMPLETEDNA

Determining the Feasibility of Outpatient Parenteral Antibiotic Therapy for Persons Who Inject Opioids

NCT05300581•Washington University School of Medicine

View on ClinicalTrials.gov

Summary

Patients with a history of injection drug use are historically excluded from home outpatient parenteral antibiotic therapy programs. Recent small pilot programs have demonstrated that these patients may be safely included in home OPAT programs when they are provided with medications for opioid use disorder such as suboxone or methadone. However nothing is known about the effect of additional social support services including case management and health coach navigation on the feasibility and acceptibility of home OPAT programs for persons who inject drugs. This observational study will provide pilot data on the feasibility of such a program in anticipation of a larger scale trial.

Eligibility

Age

18 - 100 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•English speaking males and females
•18-100 years of age
•Being considered for discharge from Barnes-Jewish Hospital on OPAT\* (PICC/Midline only) for a serious injection related infection including; endocarditis, osteomyelitis, discitis, septic arthritis, epidural abscess, or S. aureus bacteremia. \*Note that outside of this protocol patients with a history of substance use disorder are considered for discharge on OPAT to skilled nursing facilities or other health-care locations such as BJH extended care. Patients being considered for discharge on OPAT to any of these locations are eligible for inclusion.
•History of injection opioid use within the last 1 year
•Evaluated by the joint toxicology/psychiatry addiction medicine consult service during the current inpatient admission
•Started or maintained on medications for opioid use disorder (MOUD) of either methadone, buprenorphine or buprenorphine-naloxone during admission to Barnes-Jewish Hospital
•Have a scheduled follow-up for continuation of medications for opioid use disorder in place prior to discharge. For patients on methadone this should include a scheduled appointment at a methadone clinic, or for patients on buprenorphine this can include a plan for ongoing buprenorphine/ buprenorphine-naloxone based therapy at the Washington University Infectious Diseases Clinic.
•Have met with a health coach or a member of the Bridge To Health team during their inpatient hospitalization and agree to ongoing supportive counseling after discharge.
•Be willing and able to attend in-person clinic visits within 60 days post-discharge at the Washington University Infectious Diseases Clinic.
•Have a working phone number with active voicemail, running water and electricity.

Exclusion Criteria

•Prisoner status
•Unable to provide own informed consent
•Current homelessness
•Other house-hold members reported as having active untreated substance use disorders
•Unable to attend outpatient appointments. This may include patients who are from rural areas where transportation vouchers may not provide sufficient means of making it to follow-up appointments, or other disability that would preclude transportation (paralysis, broken limbs) where the patient is unable to provide specific details as to how they would arrive at clinic appointments.

Locations (1)

Washington Univeristy

St Louis, Missouri, United States

Key Dates

Start Date

March 16, 2022

Primary Completion Date

December 19, 2025

Completion Date

December 19, 2025

Last Updated

December 29, 2025

Enrollment

ACTUAL participants

Conditions

Opioid Use Disorder

Interventions

OPAT for PWID

OTHER

Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder

NCT06651177

Opioid Use DisorderOpioid Use Disorder, Moderate+1 more

View study

RECRUITINGNA

Teaching Health Resilience in a Hospital Setting: A Peer-led Intervention

NCT06843213

Opioid Use DisorderHarm Reduction+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 29, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Determining the Feasibility of Outpatient Parenteral Antibiotic Therapy for Persons Who Inject Opioids

Inclusion Criteria

Exclusion Criteria

Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder

Teaching Health Resilience in a Hospital Setting: A Peer-led Intervention

Using Facebook to Support Opioid Recovery Among American Indian Women

Social Functioning in Opioid Use Disorder

Opioid Adherence and Support Through Innovative Texting Strategies

OUD (Opioid Use Disorder) Target Trial